CytomX Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	141.1	138.1	101.21	53.16	37.31	68.43	Upgrade
Revenue Growth (YoY)	18.01%	36.45%	90.38%	42.48%	-45.47%	154.36%	Upgrade
Gross Profit	141.1	138.1	101.21	53.16	37.31	68.43	Upgrade
Selling, General & Admin	29.63	29.73	30.02	40.45	39.16	36.03	Upgrade
Research & Development	68.35	83.38	77.68	106.55	114.19	112.94	Upgrade
Operating Expenses	97.97	113.11	107.7	147	153.35	148.97	Upgrade
Operating Income	43.13	25	-6.48	-93.84	-116.04	-80.54	Upgrade
Interest & Investment Income	5.1	7.14	9.84	1.68	0.26	1.84	Upgrade
Currency Exchange Gain (Loss)	0	-0.04	-0.03	0.34	-0.08	-0.03	Upgrade
EBT Excluding Unusual Items	48.23	32.09	3.32	-91.82	-115.87	-78.73	Upgrade
Merger & Restructuring Charges	-	-	-	-7.5	-	-	Upgrade
Pretax Income	48.23	32.09	3.32	-99.32	-115.87	-78.73	Upgrade
Income Tax Expense	0.25	0.22	3.89	-	-	-13.91	Upgrade
Net Income	47.98	31.87	-0.57	-99.32	-115.87	-64.82	Upgrade
Net Income to Common	47.98	31.87	-0.57	-99.32	-115.87	-64.82	Upgrade
Shares Outstanding (Basic)	97	84	74	66	64	46	Upgrade
Shares Outstanding (Diluted)	97	85	74	66	64	46	Upgrade
Shares Change (YoY)	17.52%	14.82%	12.27%	2.48%	39.01%	1.79%	Upgrade
EPS (Basic)	0.50	0.38	-0.01	-1.51	-1.81	-1.40	Upgrade
EPS (Diluted)	0.49	0.38	-0.01	-1.51	-1.81	-1.40	Upgrade
Free Cash Flow	-77.68	-86.54	-56.88	-112.53	-120.64	2.95	Upgrade
Free Cash Flow Per Share	-0.80	-1.02	-0.77	-1.71	-1.88	0.06	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	30.56%	18.10%	-6.41%	-176.50%	-311.00%	-117.70%	Upgrade
Profit Margin	34.01%	23.08%	-0.56%	-186.82%	-310.54%	-94.73%	Upgrade
Free Cash Flow Margin	-55.05%	-62.66%	-56.19%	-211.67%	-323.33%	4.31%	Upgrade
EBITDA	44.7	26.76	-4.31	-91.39	-113.34	-77.97	Upgrade
EBITDA Margin	31.68%	19.38%	-4.26%	-171.91%	-	-113.94%	Upgrade
D&A For EBITDA	1.57	1.77	2.18	2.44	2.71	2.57	Upgrade
EBIT	43.13	25	-6.48	-93.84	-116.04	-80.54	Upgrade
EBIT Margin	30.56%	18.10%	-6.41%	-176.50%	-	-117.70%	Upgrade
Effective Tax Rate	0.52%	0.70%	117.12%	-	-	-	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q